Lung diffusing capacity for nitric oxide and carbon monoxide in relation to morphological changes as assessed by computed tomography in patients with cystic fibrosis by unknown
BioMed CentralBMC Pulmonary Medicine
ssOpen AcceResearch article
Lung diffusing capacity for nitric oxide and carbon monoxide in 
relation to morphological changes as assessed by computed 
tomography in patients with cystic fibrosis
Holger Dressel*1, Laura Filser1, Rainald Fischer2, Katharina Marten3, 
Ullrich Müller-Lisse4, Dorothea de la Motte1, Dennis Nowak1, 
Rudolf M Huber2 and Rudolf A Jörres1
Address: 1Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-University, Ziemssenstr. 1, 
D-80336 München, Germany, 2Department of Pneumology, Medizinische Klinik Innenstadt, Ludwig-Maximilians-University, Munich, Germany, 
3Department of Diagnostic Radiology, University of Göttingen, Göttingen, Germany and 4Institute for Clinical Radiology, Medizinische Klinik 
Innenstadt, Ludwig-Maximilians-University, Munich, Germany
Email: Holger Dressel* - Holger.Dressel@med.uni-muenchen.de; Laura Filser - Laura.Filser@gmx.de; 
Rainald Fischer - Rainald.Fischer@med.uni-muenchen.de; Katharina Marten - Kmarten@med.uni-goettingen.de; Ullrich Müller-
Lisse - Ullrich.Mueller-Lisse@med.uni-muenchen.de; Dorothea de la Motte - Dorothea.de.la.Motte@med.uni-muenchen.de; 
Dennis Nowak - Dennis.Nowak@med.uni-muenchen.de; Rudolf M Huber - Huber@med.uni-muenchen.de; 
Rudolf A Jörres - Rudolf.Joerres@med.uni-muenchen.de
* Corresponding author    
Abstract
Background: Due to large-scale destruction, changes in membrane diffusion (Dm) may occur in
cystic fibrosis (CF), in correspondence to alterations observed by computed tomography (CT). Dm
can be easily quantified via the diffusing capacity for nitric oxide (DLNO), as opposed to the
conventional diffusing capacity for carbon monoxide (DLCO). We thus studied the relationship
between DLNO as well as DLCO and a CF-specific CT score in patients with stable CF.
Methods: Simultaneous single-breath determinations of DLNO and DLCO were performed in 21 CF
patients (mean ± SD age 35 ± 9 y, FEV1 66 ± 28%pred). Patients also underwent spirometry and
bodyplethysmography. CT scans were evaluated via the Brody score and rank correlations (rS) with
z-scores of functional measures were computed.
Results: CT scores correlated best with DLNO (rS = -0.83; p < 0.001). Scores were also related to
the volume-specific NO transfer coefficient (KNO; rS = -0.63; p < 0.01) and to DLCO (rS = -0.79; p
< 0.001) but not KCO. Z-scores for DLNO were significantly lower than for DLCO (p < 0.001).
Correlations with spirometric (e.g., FEV1, IVC) or bodyplethysmographic (e.g., SRaw, RV/TLC)
indices were weaker than for DLNO or DLCO but most of them were also significant (p < 0.05 each).
Conclusion: In this cross sectional study in patients with CF, DLNO and DLCO reflected CT-
morphological alterations of the lung better than other measures. Thus the combined diffusing
capacity for NO and CO may play a future role for the non-invasive, functional assessment of
structural alterations of the lung in CF.
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Cystic fibrosis (CF) is characterized by the combined find-
ings of bronchiectasis and parenchymal fibrosis, which
may affect lung diffusing capacity. However, the results of
studies focussing on the diffusing capacity for carbon
monoxide (DLCO) in CF are largely contradictory, as a
spectrum of elevated, decreased, or normal values has
been reported [1,2]. Recent data in children and adults
suggest a slightly elevated DLCO in early CF and a reduc-
tion only in advanced disease [3-5]. Based on these find-
ings, DLCO currently appears to play no role in CF
assessment compared to spirometry or computed tomog-
raphy (CT) [6].
The diffusing capacity for nitric oxide (DLNO) can be used
to directly describe pulmonary membrane diffusing
capacity (Dm), without interfering with pulmonary capil-
lary blood volume (Vc). Diffusion properties of NO are
similar to those of CO; however, its rate of reaction with
red blood cells is much greater [7]. DLNO primarily reflects
Dm, whereas DLCO depends on both Dm and Vc [7]. In
combination with DLCO, Vc and Dm can be determined in
a single maneuver, based on the equation for the serial
connection of resistances [8,9].
Thus, DLNO might be superior to DLCO for quantification
of structural changes by purely functional means when
morphological changes of gas transport compartments
instead of changes in pulmonary blood volume are con-
sidered. The method of choice for the assessment of mor-
phological changes in CF is thin-section CT [10], which
also represents the gold standard for the diagnosis of
bronchiectasis [11]. Quantification of disease extent in
patients with CF can be achieved using dedicated scoring
systems focussing on different parameters, e.g. bron-
chiectasis, mucous plugging or bronchial wall thickening
[12]. Specifically, the CT scoring system developed by
Brody et al. has been shown to be a robust and reproduc-
ible tool for the semiquantitative assessment of parenchy-
mal and airway disease in CF patients [13].
The aim of our study was to correlate DLNO, DLCO and
other pulmonary function analyses with the extent of dis-
ease on CT in order to further investigate the hypothesis
that DLNO as a measure of Dm may accurately reflect mor-
phological changes in patients with CF.
Methods
Study subjects
Adult patients with CF (n = 21) in whom thin-section CTs
of the lungs were available were recruited from the Cystic
Fibrosis Outpatient Unit during routine follow-up visits.
Patients with a smoking history or with an interval of
more than 3 years between CT scans and pulmonary func-
tion tests (PFT) were excluded from the study. During the
time between the CT and the PFT the clinical status of the
patients had been regularly monitored by specialists from
the Cystic Fibrosis Outpatient unit, usually with 3 months
intervals between visits. Patients were excluded if severe
exacerbations were present when CT scans or PFTs were
performed. They were also excluded if severe exacerba-
tions were recorded during the time interval between CT
and PFT. Any exacerbation resulting in one or more days
of hospitalisation was defined as severe. The study was
approved by the local Ethics Committee and all partici-
pants gave their written informed consent.
Measurements
Simultaneous single-breath determinations of DLCO, DLNO
and alveolar volume (VA), were performed with a Master-
screen PFT (Viasys/Jaeger, Höchberg, Germany) which uses
electrochemical sensors at an inspiratory target concentra-
tion of 45 (± 5) ppm NO and a breath-hold time of 8 s [14].
Patients were seated in upright position, wearing a nose
clip. The final inspiratory gas (21% O2) was mixed from a
gas containing 448 ppm NO in N2 (Linde, Unterschleiβ
heim, Germany), a mixture of 0.28% CO and 9.5% He in
synthetic air (Viasys), and 100% oxygen and analyzed
immediately before inhalation. Maneuvers were performed
as described previously [8] and the device was calibrated at
least daily. Hb was measured in the patients and DLCO was
corrected to the standard Hb according to international
guidelines [8]. All measurements were performed threefold
with an interval of approx. 4 min, and mean values were
recorded. Values relative to volume (KNO, KCO) were
obtained by dividing DLNO and DLCO through the corre-
sponding VA. VA, DLNO and DLCO %predicted were calcu-
lated using published reference formulae [15-19]. Using a
standard approach Dm was expressed as DLNO divided by
1.97 [18], and Vc was derived as previously described [9].
Spirometry and bodyplethysmography were performed
using a pneumotachograph-based device (MasterLab™,
Viasys) following established guidelines [20]. At least
three technically acceptable flow-volume curves were
obtained and the highest values of forced expiratory vol-
ume in 1 second (FEV1) and inspiratory vital capacity
(IVC) were recorded. Airway resistance (RAW), specific air-
way resistance (SRAW), intrathoracic gas volume (ITGV),
total lung capacity (TLC) and residual volume (RV) were
also obtained.
CT examinations and scoring
As CF patients in this clinic are usually monitored by CT
every 3 years we used the most recent high resolution CT
scans obtained for routine follow-up within this period.
Among the 21 CTs, 15 had been performed on the same
day as the measurements or within the last 12 months
(mean ± SD interval: 10 ± 10 months, range: 0–33
months).Page 2 of 7
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on a clinical whole-body multidetector-row CT scanner
(Mx 8000, Philips Medical Systems, Best, The Nether-
lands), with the patient in supine position, at 120 kV, 4
× 1 mm slice collimation, 3 mm reconstruction slice
thickness, 10 mAs/slice (effective tube current-time
product), and Pitch 1.75, resulting in an effective dose of
approximately 0.5 mSv. Multiplanar image reformatting
was performed in all instances, such that axial, coronal,
and sagittal CT images were available for review on a pic-
ture archiving and communication system (PACS,
"Impax", AGFA, Munich, Germany). CT images were
evaluated by two independent experienced chest radiol-
ogists blinded to clinical or functional information,
using a validated scoring system [13]. The order in which
CTs were scored was not randomized. In detail, scores
for the presence and severity of parenchymal findings
and airway disease were calculated of each lobe, with the
lingula counted as a separate lobe. The following sub-
scores were obtained by averaging subscores across the 6
lobes in each patient: bronchiectasis, mucous plugging,
peribronchial thickening, and parenchymal disease. As
expiratory scans were not available, the air trapping sub-
score was omitted. The scoring system has been
described in detail by Brody at al. [13]. In brief, the sub-
score for bronchiectasis (possible range: 0–12) was
defined as the sum of the extent of bronchiectasis in the
central lung (0–3) and in the peripheral lung (0–3),
multiplied by the average bronchiectasis size (0–2). For
the mucous plugging score (0–6) the extent of mucous
plugging in the central lung (0–3) was added to the
extent of mucous plugging in the peripheral lung (0–3).
For the peribronchial thickening score (0–9) the sum of
the extent of peribronchial thickening in the central lung
(0–3) and the extent of peribronchial thickening in the
peripheral lung (0–3) was multiplied by the severity of
peribronchial thickening (1–1.5). The parenchyma score
(0–9) was the sum of the extent of dense parenchymal
opacity (0–3), the extent of ground glass opacity (0–3)
and the extent of cysts or bullae (0–3). Subscores were
added to obtain the total score, ranging between 0 and
36. The mean scores of both observers were used for
analysis.
Statistical analysis
Median with range or mean values and standard devia-
tions (SD) were computed. Z-scores were additionally
calculated where appropriate using published equations
[15-17,21]. The relationship between functional meas-
ures and CT scores was quantified by Spearman's rank
correlation (rS). Statistical comparisons were performed
using the Wilcoxon test. Statistical significance was
assumed for p < 0.05. To adjust the alpha level for mul-
tiple tests for correlation the Bonferroni method was
used. All analyses were performed using SPSS 14.0 (SPSS
Inc., Chicago, IL).
Results
Patient demographics and results of pulmonary function
tests are displayed in table 1. Using standard reference
equations [16], mean ± SD DLCO was 83 ± 18 %pred and
the respective z-score ± SD was -1.3 ± 1.4. According to 3
recently published reference value equations using gen-
der, age, and height as predictors, respective mean DLNO
%pred and DLCO %pred for the patient group were: 71 ±
19 and 82 ± 17 %pred [17]; 60 ± 17 and 75 ± 16 %pred
[18]; 63 ± 18 and 86 ± 19 %pred [19]. DLNO %pred was
always lower than DLCO %pred (p < 0.001 each). Z-scores
for DLNO, that could be calcuated from [17] were -2.3 ±
1.5. When comparing DLNO and DLCO expressed as z-
scores according to references [16,17], DLNO was signifi-
cantly lower than DLCO (p < 0.001). 13 subjects (62%)
had a z-score < -1.96, i.e. below the 2.5th centile concern-
ing DLNO compared to only 8 subjects (38%) concerning
DLCO.
The median (range) total CT score in our sample was 10.7
(3.4–26.5). The corresponding subscore values were 3.9
(0.8–11.2) for bronchiectasis, 1.8 (0.6–4.5) for mucous
plugging, 4.0 (0.8–8.7) for peribronchial thickening, and
1.3 (0.4–4.0) for the parenchyma subscore. The total CT
scores correlated closely between the two observers, as
indicated by the high intraclass correlation (ANOVA, R =
0.91), as well as the rank correlation coefficient (rS =
0.897; p < 0.001) and pairwise comparison according to
Wilcoxon (p = 0.465). Subscores also significantly corre-
lated between both observers (p < 0.001 each), despite
differences in bronchiectasis and parenchyma subscores
(Wilcoxon, p < 0.01 each).
Correlation coefficients between total CT scores and func-
tional measures are given in Table 2. Both DLNO and
DLCO, expressed as z-scores were related to the overall CT
score (p < 0.001 each; Figure 1, Panel A and B). Moreover,
KNO was correlated with the CT score (p = 0.002), as
opposed to KCO (Figure 2, Panel A and B). Similar results
as for the total score were obtained for the subscores.
DLNO, DLCO, Dm and Vc showed the closest correlations
with bronchiectasis, mucous plugging and peribronchial
thickening. With regard to KNO, the correlation was clos-
est for peribronchial thickening, whereas KCO was not
related to any of the subscores. The correlations between
CT scores and indices of spirometry and bodyplethysmog-
raphy were generally weaker than with DLNO and DLCO.
When adjusting the alpha level according to Bonferroni
for all correlations that were tested, the correlations of
both diffusing capacities with the overall CT score, as well
with the subscores for bronchiectasis, mucous plugging
and peribronchial thickening remained significant. Con-
cerning spirometric and bodyplethysmographic indices
the overall CT score as well as the subscores for bron-
chiectasis and peribronchial thickening remained signifi-
cantly correlated with SRAW.Page 3 of 7
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Table 1: Basic characteristics and pulmonary function tests of 21 patients (females = 8; males = 13) with CF
Mean % Predicted z-score
Age, yr 35 ± 9 - -
Height, cm 176 ± 11 - -
Weight, kg 65.5 ± 13.4 - -
VA, L 5.45 ± 1.78 87 ± 19 -1.3 ± 2.0
DLNO, mmol × min-1 × kPa-1 34.7 ± 12.2 71 ± 19 -2.3 ± 1.5
DLCO, mmol × min-1 × kPa-1 9.1 ± 2.7 83 ± 18 -1.3 ± 1.4
DLNO/DLCO 3.8 ± 0.4 § §
KNO, mmol × min-1 × kPa-1 × L-1 6.34 ± 0.91 84.7 ± 11.9 -1.9 ± 1.6
KCO, mmol × min-1 × kPa-1 × L-1 1.69 ± 0.18 81.6 ± 7.4 -1.2 ± 0.6
Dm, mmol × min-1 × kPa-1 17.6 ± 6.2 § §
Vc, mL 80 ± 25 § §
FEV1, L 2.58 ± 1.35 66 ± 28 -2.7 ± 2.3
IVC, L 4.18 ± 1.56 88 ± 23 -1.1 ± 2.1
FEV1/VC, % 59 ± 13 73 ± 15 -3.2 ± 1.8
RAW, kPa × s × L-1 0.43 ± 0.25 $ $
SRAW, kPa × s 1.97 ± 1.24 $ $
ITGV, L 4.14 ± 1.10 128 ± 27 1.6 ± 1.6
RV, L 2.90 ± 1.06 162 ± 51 2.9 ± 2.5
TLC, L 7.08 ± 1.69 108 ± 15 0.8 ± 1.4
§Not computed due to lack of sufficient and standardised data
$ Not computed, as reference equations are not commonly used for interpretation
Data are presented as mean ± SD. Abbreviations: VA = alveolar volume, DLNO = lung diffusing capacity for nitric oxide, DLCO = lung diffusing 
capacity for carbon monoxide, KNO = nitric oxide transfer coefficient, KCO = carbon monoxide transfer coefficient, Dm = membrane diffusing 
capacity, Vc = pulmonary capillary blood volume, FEV1 = forced expiratory volume in 1 s, VC = maximal inspired vital capacity, RAW = airway 
resistance, SRAW = specific airway resistance, ITGV = intrathoracic gas volume, RV = residual volume, TLC = total lung capacity. Prediction 
equations for VA according to [15], for DLCO/KCO according to [16], for DLNO/KNO according to [17], and for lung volumes according to [21].
Scatterplots for z-scores of DLNO (Panel A, rS = -0.83; p < 0.001), and DLCO (panel B, rS = -0.79; p < 0.001) against total CT s oreFigure 1
Scatterplots for z-scores of DLNO (Panel A, rS = -0.83; p < 0.001), and DLCO (panel B, rS = -0.79; p < 0.001) 
against total CT score.
A B
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We found that in patients with CF, the correlation
between DLNO as well as DLCO and CT was closer than for
indices derived from spirometry and bodyplethysmogra-
phy, including the standard measure for monitoring CF,
FEV1. Additionally, using recently published reference val-
ues [17-19], DLNO %pred was significantly lower than
DLCO %pred in CF.
At present, spirometry is the established standard in the
assessment of patients with CF, while the role of DLCO is
less well defined. This may be partially explained by the
fact that diffusion measurements are influenced by a vari-
ety of functional or structural alterations in CF, e.g. the
obstruction typically found in those patients, and thus dif-
ficult to interpret. In children with CF, DLCO has been
shown to be stable despite a decline in FEV1 %pred [4],
and in adults DLCO was found to decrease below reference
values only in patients with severe disease [3]. Based on
these and other conflicting results [2,22] it seems unlikely
that DLCO is a useful marker of disease severity in CF.
In part, these differences may be due to the fact that DLCO
essentially comprises two factors: the membrane (Dm) and
the blood component (Vc). Changes of these two compo-
nents do not necessarily correlate. In contrast to DLCO,
DLNO is thought to mainly represent Dm, thus possibly bet-
ter reflecting morphological alterations in CF. In our study
sample values of DLNO%pred were regularly significantly
lower than those for DLCO, using different reference equa-
Scatterplots for z-scores of KNO (Panel A, rS = -0.63; p = 0.002) and KCO (Panel B, rS = 0.01; n.s.) against total CT scoreFigure 2
Scatterplots for z-scores of KNO (Panel A, rS = -0.63; p = 0.002) and KCO (Panel B, rS = 0.01; n.s.) against total 
CT score.
A B
Table 2: Spearman rank coefficients between CT scores according to Brody et al. [13] and z-scores of lung function measures as 
obtained in bivariate analyses.
Bronchiectasis Mucous plugging Peribronchial thickening Parenchyma Overall CT Score
DLNO/Dm -0.78*** -0.73*** -0.79*** -0.60** -0.83***
DLCO -0.75*** -0.73*** -0.76*** -0.59** -0.79***
KNO -0.53* -0.56** -0.62** -0.40 -0.63**
KCO 0.10 0.02 0.03 0.23 0.01
Vc, mL§ -0.64** -0.58** -0.59** -0.50* -0.63**
IVC -0.50* -0.51* -0.54* -0.50* -0.55*
FEV1 -0.56** -0.53* -0.59** -0.43 -0.59**
SRAW, kPa × s$ 0.69*** 0.61** 0.71*** 0.61** 0.72***
RV 0.47* 0.43* 0.50* 0.35 0.51*
RV/TLC, %§ 0.64** 0.58** 0.65** 0.51* 0.66**
§No z-scores used due to lack of sufficient and standardised data
$ No z-scores used, as reference equations are not commonly used for interpretation
P values refer to individual pairwise correlations. Correlations remaining significant, when using Bonferroni adjusted alpha levels are indicated in 
bold. *p < 0.05;**p < 0.01;***p < 0.001, for abbreviations see Table 1Page 5 of 7
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sitive for detecting CF-related structural changes of the
lung. As different approaches were used to derive Dm and
Vc by the authors of the recently published reference equa-
tions we did not compare our derived values with these ref-
erences; further standardization of calculations seems
desirable. In this study Dm was calculated as DLNO/1.97,
whereas recently published data indicates that DLNO/2.42
may be more accurate [19]. This however does not change
correlations. Dm was more closely related with the CT score
than Vc. As DLCO consists of Dm and Vc, the strong correla-
tion with the CT score may be explained mainly by changes
in Dm. The lower sensitivity to detect CF related changes
expressed as percent of predicted values for DLCO compared
to DLNO may be due to the additional influence of the pul-
monary capillary blood volume, which is thought to be
negligible when measuring DLNO. As DLNO is thought to be
influenced by parenchymal alterations it may complement
the standard parameter measuring obstruction, FEV1. CT is
the standard measurement for structural alterations in CF,
usually performed in intervals of several years. As the meas-
urement of DLNO is non-invasive, easy to perform and
closely correlated with the CT score, it may be applied more
often during those routine visits when no CT scans are per-
formed. However, prospective longitudinal studies are
needed to decide whether the measurement of DLNO may
provide additional value to the existing standard monitor-
ing parameters.
As the reduction in diffusion capacities might be caused
by a reduction in alveolar volume, which was also corre-
lated with the CT score, we additionally assessed their val-
ues relative to alveolar volume. KCO was not related to
the CT score or its subscores, while KNO decreased with
increasing CT scores (figure 2), being specifically related
to bronchiectasis, mucus plugging and peribronchial
thickening. With decreasing VA, healthy subjects are
known to show an increase in KCO indicating an increase
in the thickness of the pulmonary capillary blood sheet
[23], while KNO is essentially stable, reflecting the diffu-
sional properties of the lung [17]. Thus, both KCO and
KNO reflect different aspects of lung morphology and
functionality. In CF, VA and/or TLC may be reduced. This
renders KNO, being less related to VA than KCO, superior
for a noninvasive assessment of membrane diffusion,
indicating structural alterations independent of volume-
dependent effects. Our data strongly support this hypoth-
esis. Zavorsky et al. recently published reference equations
for DLNO using gender and age as well as either VA or
height as predictors [19] to discern between patients with
abnormal gas exchange or low lung volume. When using
the equation including VA with our data mean ± SD pre-
dicted DLNO was 71 ± 13%, indicating abnormal gas
exchange. The equation including height instead of VA
resulted in a significantly lower predicted DLNO of 63 ±
18% (p < 0.001). According to these authors this means
that a reduction in lung volume explains part of the low
predicted DLNO. This is in line with the finding of a
slightly reduced mean VA when expressed as percent of
predicted. DLNO and DLCO also showed stronger correla-
tions with the CT score than measures derived from
spirometry and bodyplethysmography. It should be noted
that a number of correlation coefficients were rather high,
leading to only minor differences. Correlation coefficients
were comparable or slightly lower when using absolute
values instead of z-score values for DLNO and DLCO, prob-
ably reflecting the fact that lung function indices depend
on anthropometric characteristics, in contrast to CT
scores.
Among the subscores, the bronchiectasis score correlated
best with most functional measures, similar to the total
score. Indeed, bronchiectasis seems to be the most impor-
tant structural change that can be reliably scored on CT
[11]. It has even been suggested that restricting scoring to
bronchiectasis would suffice for CT monitoring in CF [6].
It should be noted that most subscores reflect airway dis-
ease, whereas DLNO and KNO are influenced mainly by
parenchymal destruction. Thus our findings show a good
correlation between a CT score as a marker of disease
severity and DLNO as a marker of parenchyma destruction.
However, a causal connection between single subscores
and the changes in diffusing capacities cannot be derived.
Thin-section CT represents the methodology of choice for
the assessment of structural alterations in CF [10]. For this
purpose, a variety of disease-specific CT scores have been
proposed [12] and it seems that further standardization of
scores is mandatory. The CT scoring system used in our
study has been demonstrated to be reproducible and sen-
sitive to disease severity [13]. CT scores are known to be
subject to considerable interobserver variability, and the
observation that for selected subscores the two experi-
enced observers differed in their rating is in line with pub-
lished data [12]. In our study the differences concerned
only the magnitude, while ratings were still correlated
with each other.
Major weaknesses of this study are its retrospective nature
and the time interval between scan and measurements of
up to 3 years with a maximum interval of 1 year in 15
patients. Moreover, the order in which CTs were scored
was not randomized. This short-coming may introduce
additional bias concerning the CT scores.
Recent studies found an annual decline of total CT scores
by -2.7% in subjects of an age range from 16 to 48 years
[24], or of -1.0% in children and -1.5% in adults [6]. One
of those studies report a corresponding decline of FEV1 by
2.3% [24] in adults. The other found that the bronchiecta-
sis score deteriorated faster than lung function parameters
in children and adults [6]. These findings suggest that thePage 6 of 7
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our results. Furthermore, only patients with a fairly stable
course of their disease were included in our study. It is,
however, reasonable to expect even higher correlations
with CT scores if these are performed at the same visit as
the functional assessments.
Conclusion
In conclusion, our findings indicated that in patients with
CF NO diffusing capacity was a functional measure that
was suitable to quantify structural changes of the lung as
assessed by CT scores. The suitability of NO diffusing
capacity is in line with previous observations in healthy
subjects or patients with other diseases than CF [25] and
renders it a challenging question of whether the com-
bined diffusing capacity for NO and CO has a potential to
be included in the assessment of CF. In this respect, the
conclusions of this retrospective cross-sectional study can
only be limited. Future longitudinal studies have to
decide over the potential of this method for the monitor-
ing of CF patients.
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